2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1209

Associations Between Rheumatoid Arthritis (RA)-Related Autoimmunity, Joint Symptoms, and Physical Activity in First-Degree Relatives without RA in a Prospective Cohort
Abstract Number: 1210

Genetic, Environmental, and Serologic Risk Factors for Inflammatory Joint Signs Among First-Degree Relatives without Rheumatoid Arthritis in a Prospective Cohort
Abstract Number: 1211

Shift of Rheumatoid Arthritis Onset Toward Old Age in Japan Based on a Nationwide Cohort Database
Abstract Number: 1212

Investigation of Vitamin D Supplement Use, Rheumatoid Arthritis-Related Autoimmunity and Joint Signs Among Those at Increased Risk for the Development of Rheumatoid Arthritis
Abstract Number: 1213

Prospective Study of Dietary Patterns and Risk of Rheumatoid Arthritis in Women
Abstract Number: 1214

Rheumatoid Arthritis in Female Spouses in the Agricultural Health Study: Associations with Pesticides and Other Farm Exposures
Abstract Number: 1215

Air Pollution and the Rheumatic Diseases: A Systematic Review and Meta-Analysis
Abstract Number: 1216

The Clinical and Ultrasonographic Presentation of Seronegative RA Is More Severe Compared to Seropositive RA in an Inception Cohort of DMARD-Naïve Patients Classified According to the 2010 ACR/EULAR Criteria
Abstract Number: 1217

Phenome-Wide Association Study of Novel Anti-Citrullinated Peptide Antibodies in Rheumatoid Arthritis
Abstract Number: 1218

Higher Education Is Associated with a Better Rheumatoid Arthritis Outcome Concerning Pain and Function but Not Disease Activity: Results from Swedish Registers
Abstract Number: 1219

Prevalence and Clinical Characteristics of Rheumatoid Arthritis in Poland: First Nationwide Study
Abstract Number: 1220

Oral Glucocorticoid Prescribing Patterns in UK Primary Care for Patients with Rheumatoid Arthritis
Abstract Number: 1221

Characteristics and Outcomes of RA Patients Who Start Biosimilar Infliximab in South Korea
Abstract Number: 1222

The Risk of Tuberculosis (TB) in Rheumatoid Arthritis Patients Treated with TNF Inhibitors and the Safety of Resuming Biologic Dmards for Patients Who Developed TB after Anti-TNF Treatment
Abstract Number: 1224

Infection Rate in HIV Patients Who Received TNF-a Inhibitor Therapy for Concomitant Autoimmune Diseases

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].